CA2435835A1 - Combinaisons d'uroguanyline et d'inhibiteur de cyclooxygenase-2 pour l'inhibition du cancer de l'intestin - Google Patents

Combinaisons d'uroguanyline et d'inhibiteur de cyclooxygenase-2 pour l'inhibition du cancer de l'intestin Download PDF

Info

Publication number
CA2435835A1
CA2435835A1 CA002435835A CA2435835A CA2435835A1 CA 2435835 A1 CA2435835 A1 CA 2435835A1 CA 002435835 A CA002435835 A CA 002435835A CA 2435835 A CA2435835 A CA 2435835A CA 2435835 A1 CA2435835 A1 CA 2435835A1
Authority
CA
Canada
Prior art keywords
composition
amino acid
group
acid residues
glycine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002435835A
Other languages
English (en)
Inventor
Jaime L. Masferrer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2435835A1 publication Critical patent/CA2435835A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une méthode destinée à retarder le développement de polypes et de prévention, d'inhibition et de traitement du cancer dans l'intestin d'un sujet consistant en l'administration d'une composition contenant un peptide présentant le domaine actif de l'uroguanyline ou de n'importe quel peptide ou composé agoniste se fixant au récepteur guanylate cyclase GC-C dans l'intestin, en combinaison avec un inhibiteur de cyclooxygénase-2 naturel, dérivé d'un inhibiteur de cyclooxygénase-2 naturel ou un inhibiteur de cyclooxygénase-2 synthétisé par voie chimique, de préférence un inhibiteur de cyclooxygénase-2 sélectif.
CA002435835A 2001-02-02 2002-02-04 Combinaisons d'uroguanyline et d'inhibiteur de cyclooxygenase-2 pour l'inhibition du cancer de l'intestin Abandoned CA2435835A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26595501P 2001-02-02 2001-02-02
US60/265,955 2001-02-02
PCT/US2002/003201 WO2002062369A2 (fr) 2001-02-02 2002-02-04 Combinaisons d'uroguanyline et d'inhibiteur de cyclooxygenase-2 pour l'inhibition du cancer de l'intestin

Publications (1)

Publication Number Publication Date
CA2435835A1 true CA2435835A1 (fr) 2002-08-15

Family

ID=23012573

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002435835A Abandoned CA2435835A1 (fr) 2001-02-02 2002-02-04 Combinaisons d'uroguanyline et d'inhibiteur de cyclooxygenase-2 pour l'inhibition du cancer de l'intestin

Country Status (5)

Country Link
EP (1) EP1365753A2 (fr)
JP (1) JP2004521123A (fr)
AU (1) AU2002235520A1 (fr)
CA (1) CA2435835A1 (fr)
WO (1) WO2002062369A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103641892B (zh) * 2001-03-29 2015-06-17 药物协和公司 用于治疗组织炎症和癌变的鸟苷酸环化酶受体激动剂
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
SG168407A1 (en) 2003-01-28 2011-02-28 Ironwood Pharmaceuticals Inc Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
PL1644021T3 (pl) 2003-06-13 2013-01-31 Ironwood Pharmaceuticals Inc Sposoby i kompozycje do leczenia zaburzeń żołądkowo-jelitowych
US7494979B2 (en) 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2527360B1 (fr) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
EP2810951B1 (fr) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
EP2296685B1 (fr) 2008-06-04 2015-09-02 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utiles dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
EP3241839B1 (fr) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
CN117530912A (zh) 2008-08-15 2024-02-09 硬木药品公司 适合口服给药的鸟苷酸环化酶-c受体激动剂多肽的稳定的固体制剂
US20120039949A1 (en) * 2008-09-04 2012-02-16 Ironwood Pharmaceuticals, Inc. Stable Solid Formulations of GC-C Receptor Agonist Polypeptides Suitable for Oral Administration
CA2994066A1 (fr) 2008-12-03 2010-06-10 Synergy Pharmaceuticals, Inc. Formulations d'agonistes de guanylate cyclase c et methode d'utilisation
CA2770077A1 (fr) 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprenant du linaclotide
US8933030B2 (en) 2010-02-17 2015-01-13 Ironwwod Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
DK2603232T3 (da) 2010-08-11 2019-12-09 Ironwood Pharmaceuticals Inc Stabile formuleringer af linaclotid
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2621509A4 (fr) * 2010-09-15 2016-08-03 Synergy Pharmaceuticals Inc Préparations d'agonistes du guanylate cyclase-c et méthodes d'utilisation
US9708371B2 (en) 2011-08-17 2017-07-18 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
CA2905438A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation

Also Published As

Publication number Publication date
JP2004521123A (ja) 2004-07-15
EP1365753A2 (fr) 2003-12-03
WO2002062369A3 (fr) 2003-08-28
WO2002062369A2 (fr) 2002-08-15
AU2002235520A1 (en) 2002-08-19

Similar Documents

Publication Publication Date Title
CA2435835A1 (fr) Combinaisons d'uroguanyline et d'inhibiteur de cyclooxygenase-2 pour l'inhibition du cancer de l'intestin
AU745797B2 (en) Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
US5990148A (en) Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
US20030220374A1 (en) Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20040147581A1 (en) Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
EP1397145B1 (fr) Utilisation d'inhibiteurs de cyclo-oxygenase-2 pour le traitement de la schizophrenie, ou de tics
US20030212138A1 (en) Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
MXPA04010888A (es) Combinacion de inhibidores de ciclooxigenasa-2 y talidomida para el tratamiento de neoplasia.
US20050119262A1 (en) Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
JP2007509968A (ja) 新形成を治療または予防するためのｈｓｐ９０阻害剤およびホスホジエステラーゼ阻害剤を含む組み合わせ
KR20040072720A (ko) 항바이러스제와 함께 사용되는 유두종 바이러스 감염의치료를 위한 ｃｏｘ-2 억제제의 용도
US20030157061A1 (en) Combinations of a cyclooxygenase-2 selective inhibitor and a TNFalpha antagonist and therapeutic uses therefor
US20040121961A1 (en) Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
JP2007526328A (ja) 単独および抗うつ薬と組み合わせた形のＣｏｘ−２阻害剤によって精神障害を治療または予防するための方法および組成物
JP2005500259A (ja) 癌の治療の薬剤及び方法
US20020035156A1 (en) Combination therapy in the prevention of cardiovascular disorders
JP2006524259A (ja) Ｃｏｘ−２インヒビターとアロマターゼ・インヒビターとの治療的併用薬
JP2006523715A (ja) 新生物形成の治療のためのｃｏｘ−２阻害薬とアルキル化型抗新生物剤との組合せ医薬
US20030207846A1 (en) Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
WO2005020926A2 (fr) Traitement ou prevention de troubles vasculaires au moyen d'inhibiteurs de cox-2 associee a des inhibiteurs de la phosphodiesterase specifique de l'amp cyclique
US20070072861A1 (en) Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
US20050004224A1 (en) Treatment of Alzheimer's disease with the R(-) isomer of a 2-arylpropionic acid non-steroidal anti-inflammatory drug alone or in combination with a cyclooxygenase-2 selective inhibitor
MXPA99009495A (en) Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
CZ9903642A3 (cs) Použití inhibitorů cyklooxygenasy-2 pro prevenci kardiovaskulárních onemocnění

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20080204